Bio-Techne misses revenue estimates as US academic funding cuts dent demand

May 6 (Reuters) - Biotech firm Bio-Techne on Wednesday missed Wall Street estimates for third-quarter revenue, as cuts to U.S. academic funding weighed on demand for its drug-development products.
StockStory.org on MSN

Bio-Techne (NASDAQ:TECH) reports sales below analyst estimates in Q1 CY2026 earnings

Life sciences company Bio-Techne (NASDAQ:TECH) in Q1 CY2026, with sales falling 1.5% year on year to $311.4 million. Its ...
The Motley Fool

Is Bio-Techne Stock a Buy, Sell, or Hold After a Wealth Manager Dumps Its Entire Stake?

Hollow Brook Wealth Management sold its entire position in Bio-Techne -- 174,677 shares -- during the fourth quarter of 2025, for an estimated $10.7 million based on quarterly average pricing. The ...
TMCnet

Bio-Techne Declares Dividend

For more information on Bio-Techne and its brands, please visit or follow the company on social media at LinkedIn , X , or YouTube . Forward Looking Statements: Our press releases may contain forward ...
Morningstar

Bio-Techne Announces Changes to its Leadership Team

Dr. Matt McManus to transition from his role as President, Diagnostics and Spatial Biology Segment, effective March 1, 2026 Steve Crouse, Senior Vice President of Bio-Techne's Analytical Solutions ...
Benzinga.com

Bio-Techne Stock Upgraded As Analyst Flags Attractive Entry Point

RBC Capital on Tuesday upgraded Bio-Techne Corporation (NASDAQ:TECH), noting that recent end-market weakness has over-penalized one of the best assets in the life science and tools (LST) sector, ...
Seeking Alpha

Bio-Techne: Solid Financial Ground In The Face Of Macroeconomic Uncertainty

The DCF model implemented in this article suggests that Bio-Techne is overvalued by 34.53%. Bio-Techne has allocated significant financial resources to capex. Due to these resources, its revenues ...
Morningstar

Bio-Techne Advances Spatial Biology with Modular Expansion of COMET™ Suite

New SPYRE™ Focus Panels (Stroma and Vessel) broaden modular panel options, enabling deeper targeted insights in spatial biology workflows. SPYRE™ Amplification Kits leverage sequential and enhanced ...
manilatimes

Bio-Techne Introduces Streamlined Brand Architecture to Help Customers Navigate Solutions Faster and With Greater Clarity

Bio-Techne introduces a streamlined brand architecture that organizes its technologies into three focused portfolio brands: R&D Systems™, Bio-Techne Spatial™, and Bio-Techne Diagnostics™. The ...

Bio-Techne expects Q4 organic growth approximately flat while targeting ~100 bps margin expansion

Q3 fiscal 2026 Management View "The Bio-Techne team continued to execute with discipline in a dynamic and uneven end market environment" and said results were supported by "sustained strength from our ...